TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26170622

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day
Number of subjects: 210
Study: 23842215

Group type: EXPERIMENTAL
Intervention: Midodrine (12.5 mg 3 times/d; over 3 d)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Albumin (8 g/L of removed ascites)
Number of subjects: 50
Study: 22468094

Group type: EXPERIMENTAL
Intervention: tacrolimus, basiliximab, and mycophenolate mofetil with steroid withdrawal
Number of subjects: 30

Group type: COMPARATOR
Intervention: steroid treatment (control group)
Number of subjects: 30
Study: 19242829

Group type: EXPERIMENTAL
Intervention: 5-FU and Levamisole (Lev)
Number of subjects: 425

Group type: COMPARATOR
Intervention: Control (surgery alone)
Number of subjects: 425
Study: 17446248

Group type: EXPERIMENTAL
Intervention: Risk Watch program
Number of subjects: 459
Study: 15382102

Group type: EXPERIMENTAL
Intervention: Four-layer bandage
Number of subjects: 387

Group type: COMPARATOR
Intervention: Short-stretch bandage
Number of subjects: 387
Study: 11451595

Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD) with Polymyxin E, Tobramycin, and Amphotericin B
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 9677847

Group type: EXPERIMENTAL
Intervention: AO osteosynthesis (A group)
Number of subjects: 219

Group type: COMPARATOR
Intervention: External fixator (B group)
Number of subjects: 219
Study: 8295321

Group type: EXPERIMENTAL
Intervention: Lovastatin (10 mg/d)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: LDL turnover study
Number of subjects: 26
Study: 3068596

Group type: EXPERIMENTAL
Intervention: Alcohol (blood concentration of approximately 0.08%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol (white light)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol (green light)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol (red light)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol (blue light)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol (short interval of 40 min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol (long interval of 60 min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no alcohol)
Number of subjects: 0
Study: 30130429

Group type: EXPERIMENTAL
Intervention: Control impairment (CI) in sagittal plane
Number of subjects: 24

Group type: COMPARATOR
Intervention: No control impairment (CI) in sagittal plane
Number of subjects: 24
Study: 30681515

Group type: EXPERIMENTAL
Intervention: S3/30-CXL
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: A9/10-CXL
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: A30/4-CXL
Number of subjects: 93
Study: 25476448

Group type: EXPERIMENTAL
Intervention: HT7 verum acupuncture
Number of subjects: 120

Group type: COMPARATOR
Intervention: HT7 non‐penetrating sham acupuncture
Number of subjects: 120

Group type: COMPARATOR
Intervention: Acupuncture at a sham point
Number of subjects: 120

Group type: COMPARATOR
Intervention: No acupuncture
Number of subjects: 120
Study: 23490655

Group type: COMPARATOR
Intervention: CMF chemotherapy (n=117)
Number of subjects: 647

Group type: COMPARATOR
Intervention: Observation (n=125)
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Low-uPA/PAI-1 patients
Number of subjects: 647

Group type: COMPARATOR
Intervention: CMF chemotherapy (per-protocol analysis)
Number of subjects: 647
Study: 21185977

Group type: EXPERIMENTAL
Intervention: Nutrition education program (six weekly interactive lessons based on the Theory of Planned Behavior)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control group (six weekly nonrelated financial lessons by mail)
Number of subjects: 141
Study: 18559141

Group type: COMPARATOR
Intervention: Self-regulation training for kindergarten teachers
Number of subjects: 132
Study: 17578321

Group type: EXPERIMENTAL
Intervention: Chinese herbal decoctions (Shitong mixture No. 1 before laparoscopic cholecystectomy, Liujunzi decoction after laparoscopic cholecystectomy for three days)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Conventional Western medicine and placebo
Number of subjects: 360
Study: 15489577

Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg) administered as three intravenous infusions
Number of subjects: 13

Group type: COMPARATOR
Intervention: High-dose prednisolone (1.5 mg/kg daily for 2 weeks, followed by 1 mg/kg for 1 week, then weekly reduction of 5 mg)
Number of subjects: 13
Study: 11597530

Group type: EXPERIMENTAL
Intervention: 5 mg GTN patches
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 50
Study: 9699139

Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD) regimens (PTA, PCA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8040999

Group type: EXPERIMENTAL
Intervention: Nebulised solutions of saliva
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nebulised solutions of isotonic saline
Number of subjects: 15
Study: 3141188

Group type: EXPERIMENTAL
Intervention: Percutaneous nitroglycerin paste (10 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nitroglycerin ointment (5 mg)
Number of subjects: 10
Study: 29110615

Group type: EXPERIMENTAL
Intervention: H2-water (300 mL per day)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo water (control group)
Number of subjects: 73
Study: 28709081

Group type: EXPERIMENTAL
Intervention: Usual care with contingency management incentives for treatment attendance (CM-Att; n=30)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Usual care with contingency management for each day of no drinking per SCRAMx (CM-Abst; n=17)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care (n=36)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care (n=17)
Number of subjects: 100
Study: 26183437

Group type: EXPERIMENTAL
Intervention: Travalert dosing aid
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Morisky Measure of Adherence Scale
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Frequency of Missed Dose self-report measures
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Medication possession ratio
Number of subjects: 208
Study: 23918028

Group type: EXPERIMENTAL
Intervention: Warmed intravenous infusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 21225321

Group type: EXPERIMENTAL
Intervention: Active or passive relaxation exercises
Number of subjects: 39
Study: 18793578

Group type: EXPERIMENTAL
Intervention: Remifentanil (dosing details not specified)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: LC-MS/MS method for quantification of remifentanil
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Population pharmacokinetic model
Number of subjects: 15
Study: 16414395

Group type: EXPERIMENTAL
Intervention: Pale sulfonated shale oil (PSSO) 10% applied daily for 20 weeks
Number of subjects: 119

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: PSSO
Number of subjects: 119
Study: 15282660

Group type: EXPERIMENTAL
Intervention: Recombinant platelet factor 4 (rPF4) at doses of 0.5, 1.0, 2.5, or 5.0 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Protamine
Number of subjects: 0
Study: 11523384

Group type: EXPERIMENTAL
Intervention: NNTs derived from systematic reviews and meta-analyses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pooled absolute risk differences in meta-analyses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pooled relative risk reductions
Number of subjects: 0
Study: 9740864

Group type: EXPERIMENTAL
Intervention: Rilmenidine 1 mg/d
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Rilmenidine
Number of subjects: 41
Study: 8376914

Group type: EXPERIMENTAL
Intervention: ridogrel 300 mg b.i.d.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Combination of ridogrel 300 mg b.i.d. and ketanserin 20 mg t.i.d.
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Combined treatment with ridogrel and ketanserin during 3-month follow-up
Number of subjects: 27
Study: 3769491

Group type: EXPERIMENTAL
Intervention: Simultaneous, symmetric, bihemifield stimuli (SSBS)
Number of subjects: 0
Study: 28750153

Group type: EXPERIMENTAL
Intervention: 595-nm Pulsed-Dye Laser (PDL)
Number of subjects: 61

Group type: COMPARATOR
Intervention: 595-nm Pulsed-Dye Laser (PDL) + 1064-nm Nd:YAG (DWL)
Number of subjects: 61
Study: 26711164

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Health education
Number of subjects: 255

Group type: COMPARATOR
Intervention: Brief advice
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing and health education
Number of subjects: 255
Study: 24930649

Group type: EXPERIMENTAL
Intervention: SD-101 breath detection monitor
Number of subjects: 101

Group type: COMPARATOR
Intervention: Polysomnography (PSG)
Number of subjects: 101
Study: 22956204

Group type: EXPERIMENTAL
Intervention: Ropivacaine wound infusion (0.5%)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 48
Study: 20818902

Group type: EXPERIMENTAL
Intervention: Intensive blood-pressure control
Number of subjects: 1094

Group type: COMPARATOR
Intervention: Standard blood-pressure control
Number of subjects: 1094
Study: 18544469

Group type: EXPERIMENTAL
Intervention: Delta9‐THC
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Standardized cannabis extract containing Delta9‐THC and CBD
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (implied control)
Number of subjects: 20
Study: 15660547

Group type: EXPERIMENTAL
Intervention: Soft music (six 45‐minute sedative music tapes) for 3 weeks
Number of subjects: 60
Study: 12689884

Group type: EXPERIMENTAL
Intervention: Verteporfin therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 120
Study: 10735922

Group type: EXPERIMENTAL
Intervention: Furazolidone 200 mg b.d. (RABF)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Metronidazole 500 mg b.d. (RABM)
Number of subjects: 106
Study: 8960592

Group type: EXPERIMENTAL
Intervention: 500 mg/day of oral ascorbic acid
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (51 patients)
Number of subjects: 50
Study: 1305155

Group type: EXPERIMENTAL
Intervention: Citric acid treatment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Root planing alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Root planing in conjunction with citric acid treatment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: No treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (10 nondiseased, untreated teeth)
Number of subjects: 40
Study: 3895033

Group type: EXPERIMENTAL
Intervention: mesulergine (mean dosage, 27.4 mg/d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: bromocriptine (mean dosage, 40.8 mg/d)
Number of subjects: 20
Study: 29975283

Group type: EXPERIMENTAL
Intervention: Combined circuit exercise (60 min/day, 3 days/week for 12 weeks)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combined circuit exercise
Number of subjects: 24
Study: 27450487

Group type: EXPERIMENTAL
Intervention: MTX+ozone
Number of subjects: 60

Group type: COMPARATOR
Intervention: MTX
Number of subjects: 60
Study: 24673474

Group type: EXPERIMENTAL
Intervention: Cetirizine and Hydroxyzine
Number of subjects: 92

Group type: COMPARATOR
Intervention: Desloratadine, Levocetirizine, and Rupatadine
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Pheniramine and Rupatadine
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Classic Antihistamines
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: New-generation Antihistamines
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Rupadatine and Pheniramine
Number of subjects: 92
Study: 22925074

Group type: EXPERIMENTAL
Intervention: Flaxseed extract (1 g/day, containing at least 100 mg of SDG)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Flaxseed meal (90 g/day, containing at least 270 mg of SDG)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Collagen (1 g/day, placebo group)
Number of subjects: 90
Study: 20116706

Group type: EXPERIMENTAL
Intervention: Single-dose antibiotic prophylaxis
Number of subjects: 150

Group type: COMPARATOR
Intervention: Single-day antibiotic prophylaxis
Number of subjects: 150
Study: 18589558

Group type: COMPARATOR
Intervention: Tacrolimus 5 mg capsules under fasting conditions
Number of subjects: 92

Group type: COMPARATOR
Intervention: Tacrolimus 5 mg capsules under fed conditions
Number of subjects: 92
Study: 16188130

Group type: EXPERIMENTAL
Intervention: Gendicine combined with radiotherapy (GTRT)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Radiotherapy alone (RT)
Number of subjects: 69
Study: 12240572

Group type: EXPERIMENTAL
Intervention: Bilamellar Tarsal Rotation (BTR)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Tarsotomy (TTR)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Comparison of BTR and TTR
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: BTR
Number of subjects: 153
Study: 9681664

Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Noradrenaline
Number of subjects: 16
Study: 8116134

Group type: EXPERIMENTAL
Intervention: Orchiectomy plus estramustine phosphate (EMP), 2 x 280 mg/day
Number of subjects: 99

Group type: COMPARATOR
Intervention: Orchiectomy plus flutamide, 3 x 250 mg/day
Number of subjects: 99
Study: 3220007

Group type: EXPERIMENTAL
Intervention: sulbactam 250 mg plus ampicillin 500 mg intravenously
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: sultamicillin equivalent to sulbactam 294 mg plus ampicillin 440 mg orally
Number of subjects: 10

Group type: COMPARATOR
Intervention: clavulanic acid 100 mg plus amoxycillin 500 mg intravenously
Number of subjects: 10

Group type: COMPARATOR
Intervention: clavulanic acid 125 mg plus amoxycillin 500 mg orally
Number of subjects: 10
Study: 31903588

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (loading dose of 0.6 μg/kg 10 min before induction followed by continuous infusion of 0.5 μg/kg/h until 1h before end of surgery)
Number of subjects: 619

Group type: COMPARATOR
Intervention: Normal saline (volume-matched, same schedule as dexmedetomidine)
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 619

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 619
Study: 30315206

Group type: EXPERIMENTAL
Intervention: Daily PrEP with TDF-FTC
Number of subjects: 0
Study: 26821042

Group type: EXPERIMENTAL
Intervention: 30% protein diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20% protein diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: 10% protein diet
Number of subjects: 0
Study: 24529292

Group type: EXPERIMENTAL
Intervention: Test formulation (wet-granulation tablet)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Reference formulation (dry-granulation tablet)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 60
Study: 23682639

Group type: EXPERIMENTAL
Intervention: Short sleep (4 h)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Habitual sleep (9 h)
Number of subjects: 27
Study: 21737124

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OCs) with 20 μg estrogen
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OCs) with 30 μg estrogen
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OCs) with 35 μg estrogen
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OCs) with 50 μg estrogen
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Women carrying the 1601GG genotype
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Women carrying the 1601GA genotype
Number of subjects: 588
Study: 19251767

Group type: EXPERIMENTAL
Intervention: Smoking cues in antismoking advertisements (weak argument condition)
Number of subjects: 96

Group type: COMPARATOR
Intervention: No cue in antismoking advertisements
Number of subjects: 96
Study: 16728513

Group type: EXPERIMENTAL
Intervention: Sustained knee extension at 2.5% MVC force for 1 h
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Frequency of alternate muscle activity for RF-VL and RF-VM pairs
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Frequency of alternate muscle activity for VL-VM pair
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Correlation of alternate muscle activity with MVC force reduction
Number of subjects: 41
Study: 15306618

Group type: EXPERIMENTAL
Intervention: Labeling program plus educational program
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Labeling program
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Food supply program plus educational program
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Educational program
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 17
Study: 11507356

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg twice a day, amoxycillin 1 g twice a day, tinidazole 500 mg twice a day (FAT group; n = 60)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Omeprazole 20 mg twice a day, amoxycillin 1 g twice a day, tinidazole 500 mg twice a day (OAT group; n = 60)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Famotidine (FAT group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Omeprazole (OAT group)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Metronidazole resistance
Number of subjects: 120
Study: 9414378

Group type: EXPERIMENTAL
Intervention: One layer of cotton gloves
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Two layers of cotton and rubber gloves
Number of subjects: 40

Group type: COMPARATOR
Intervention: Barehanded condition
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Operating height at shoulder
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Operating height at elbow
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Operating height overhead
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Handwheel diameters ranging from 75 to 95 mm for males
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Handwheel diameters ranging from 65 to 80 mm for females
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Average R/U MVTE for females
Number of subjects: 40
Study: 8499376

Group type: EXPERIMENTAL
Intervention: Single ablation-zone PRK
Number of subjects: 24

Group type: COMPARATOR
Intervention: Double ablation-zone PRK
Number of subjects: 24
Study: 6233550

Group type: EXPERIMENTAL
Intervention: Blo-Bag with Duovent metered dose inhaler
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metered dose inhaler alone
Number of subjects: 0
Study: 31436839

Group type: EXPERIMENTAL
Intervention: Nelfinavir mesylate, 625 mg, twice daily
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Nelfinavir mesylate, 1250 mg, twice daily
Number of subjects: 35
Study: 29549533

Group type: EXPERIMENTAL
Intervention: Patient-reported RP-related symptoms during the last week of CRT
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Moderate/severe patient-rated RP-related symptom score (≥ 4 on a 0-10 scale)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Normal-lung FDG uptake (SUVmean > 0.78)
Number of subjects: 132
Study: 27002446

Group type: EXPERIMENTAL
Intervention: Covered self-expandable metallic stents (cSEMS)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Plastic stents
Number of subjects: 112
Study: 25313756

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 62
Study: 22374335

Group type: EXPERIMENTAL
Intervention: Pharmacogenetic algorithms derived from Asian patients
Number of subjects: 282

Group type: COMPARATOR
Intervention: Pharmacogenetic algorithms derived from Caucasian patients
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Algorithms with additional covariates of INR values
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Algorithms with additional covariates of CYP4F2*3
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Algorithms from Caucasian and racially mixed populations
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Algorithms from Asian populations
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: All algorithms
Number of subjects: 282
Study: 20586515

Group type: EXPERIMENTAL
Intervention: Tapentadol ER 100-250 mg twice daily
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: Oxycodone CR 20-50 mg twice daily
Number of subjects: 1030

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1030
Study: 18036103

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA); taken by 22 patients
Number of subjects: 27

Group type: COMPARATOR
Intervention: Pre-UDCA period
Number of subjects: 27

Group type: COMPARATOR
Intervention: Post-UDCA period
Number of subjects: 27
Study: 17901137

Group type: EXPERIMENTAL
Intervention: Ultrasound landmarks (ULs)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Palpation landmarks (PLs)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Ultrasound landmarks (ULs) in obese patients
Number of subjects: 46

Group type: COMPARATOR
Intervention: Palpation landmarks (PLs) in obese patients
Number of subjects: 46
Study: 15168172

Group type: EXPERIMENTAL
Intervention: Water Pik irrigator with subgingival tip (tap water)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Water Pik irrigator with subgingival tip (herbal mouth rinse)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no irrigator or irrigant)
Number of subjects: 45
Study: 10751029

Group type: EXPERIMENTAL
Intervention: Zafirlukast solution (40 mg) administered orally
Number of subjects: 5

Group type: COMPARATOR
Intervention: Zafirlukast solution (40 mg) administered via oroenteric tube into the colon
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Zafirlukast solution (40 mg) administered into the distal ileum
Number of subjects: 5
Study: 8925829

Group type: EXPERIMENTAL
Intervention: Enalapril (ENAL), an angiotensin converting enzyme inhibitor (ACE-I), 5 mg acute administration
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Enalapril (ENAL)
Number of subjects: 9
Study: 1336475

Group type: EXPERIMENTAL
Intervention: Enalapril treatment
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sclerotherapy + placebo
Number of subjects: 12